(1994). Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat
(1996). BZ: Interleukin 6 induces the expression of vascular endothelial growth factor.
(1998). Catalano G: Serum levels of interleukin 6 as a prognostic factor in advanced nonsmall cell lung cancer. Oncol Rep
(2000). Cytokine variations in patients with hormone treated prostate cancer.
(2008). Ezaki T: Preoperative elevation of serum Creactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today
(1982). Griffiths K: A prognostic index in primary breast cancer.
(1987). Haybittle JL: Confirmation of a prognostic index in primary breast cancer.
(2004). Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA
(2007). LA: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol
(2007). ML: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/ RhoA/ROCK signaling pathway.
(1992). Moskovtchenko JF: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res
(1991). NE: Breast screening, prognostic factors and survival–results from the Swedish two county study.
(2006). Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients.
(1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.
(2000). RA: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet
(2000). S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histological grade in a prospective study of premenopausal lymph node-negative breast cancer.
(2000). Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res
(1999). TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
(1999). TC: The natural history of breast carcinoma: what have we learned from screening? Cancer
(1957). WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 539 have been followed up for 15 years.